Observational studies at the SCAI meeting favored the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) over ...

A rapidly growing heart failure epidemic calls for prioritizing primary prevention, according to a new scientific statement ...

The overall rate of cardiovascular death or worsening heart failure, the trial's primary endpoint, was higher in the 60% of study participants who also had chronic kidney disease. However ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

Compare Dialysis Centers examined CDC data and other sources to explore kidney disease risk factors and why the condition has ...

Anemia is highly prevalent in patients with chronic heart failure (HF ... erythropoietin therapy in anemic patients with chronic kidney disease and concomitant heart disease have demonstrated ...

A Swedish study shows that the risk for cardiovascular diseases is elevated in patients with chronic hypoparathyroidism, ...

A silent but rapidly rising tide of heart failure cases that's turning into an epidemic, one that the American Heart ...

A new study from University Hospitals Connor Whole Health found that it was feasible to conduct a hybrid music therapy intervention for patients with heart failure and patients with chronic ...

The overall rate of cardiovascular death or worsening heart failure, the trial’s primary endpoint, was higher in the 60% of study participants who also had chronic kidney disease. However, tirzepatide ...

A Diabetes, Heart Failure, and Kidney Disease Medication ... New Method Predicts Worsening of Chronic Kidney Disease Sep. 12, 2024 — Researchers have developed a new method that could be a ...

CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or heart failure with mildly reduced or preserved ejection ...